Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 3Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13Pancreatic Neoplasms 13

Interventions

HhAntag691 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Hemangiosarcoma × Clear all
NCT01154452 2018-08-15

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
78 enrolled 11 charts
GastrointestinalSarcoma

Malignant mesenchymal tumor, Chondrosarcoma, Extraskeletal Myxoid, Chondrosarcoma, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Neuroectodermal Tumors, Primitive, Peripheral, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡